QUARTERLY EARNINGS

A labourer carries coal in a basket to load it in a truck at a coal store in Chandigarh October 25, 2010. REUTERS/Ajay Verma/Files

Coal India Dec-qtr net jumps 54 pct

State-run miner Coal India posted a better-than-expected 54 percent rise in its December-quarter net profit, helped by strong production volumes and a price increase effected last February.  Full Article 

  • Most Popular
  • Most Shared

Reuters Showcase

Photo

India Auto Market

India's carmakers on fast track to capacity glut.  Full Article 

Managing the Currency

Managing the Currency

Rupee defence succeeds -- for now.  Full Article 

Proping up Rupee

Proping up Rupee

RBI's Dec FX market intervention biggest in 3-1/2 years.  Full Article 

Debt Woes

Debt Woes

Greece still to convince Europe after rescue deal.  Full Article 

Mr Scissorhands

Mr Scissorhands

S&P's Moritz Kraemer: Europe's AAA-rated Mr Scissorhands.  Full Article 

Cyber Attack

Cyber Attack

Microsoft India store down after hackers take user data.  Full Article 

A Glimmer of Hope

A Glimmer of Hope

Investors peer past gloom, eye Asian economic rebound.  Full Article 

Reputation Matters

Reputation Matters

Apple pops, Wall Street firms drop in brand study.  Full Article 

Buy, Sell or Hold?

Buy, Sell or Hold?

Stock recommendations from VantageTrade.  Full Coverage 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage 

Aurobindo Pharma gets US nod for seizure drug

Stocks

   

From the Financial Times

India should be wary of Europe trade negotiations

MUMBAI | Fri Nov 6, 2009 11:06am IST

MUMBAI Nov 6 (Reuters) - India's Aurobindo Pharma Ltd (ARBN.BO) said on Friday it secured final approval from the U.S. Food and Drug Administration for Lamotrigine tablets, used in the treatment of partial and generalised seizures.

The drug is the generic equivalent of Lamictal CD tablets, a brand of GlaxoSmithkline (GLAX.BO), it said in a statement to the BSE. (Reporting by Tamajit Pain; Editing by Prem Udayabhanu)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.